WASHINGTON — If President Biden wants major pharmaceutical industry reforms, he may have to achieve them on his own.
That’s looking increasingly likely after the White House’s concession on Thursday that it is abandoning its push for Congress to include major drug pricing provisions in its long-debated social spending bill.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
